Ultragenyx Pharmaceutical (RARE) Raised to “Sell” at BidaskClub

BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a strong sell rating to a sell rating in a research report released on Friday morning.

A number of other equities research analysts have also recently issued reports on RARE. Piper Jaffray Companies boosted their target price on shares of Ultragenyx Pharmaceutical to $85.00 and gave the company an overweight rating in a research report on Friday, August 3rd. Barclays reissued an overweight rating and issued a $92.00 target price (up previously from $74.00) on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 3rd. Robert W. Baird reissued a buy rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 3rd. Canaccord Genuity boosted their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the company a buy rating in a research report on Friday, August 3rd. Finally, Wedbush boosted their target price on shares of Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an outperform rating in a research report on Monday, August 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $75.95.

RARE stock opened at $53.28 on Friday. Ultragenyx Pharmaceutical has a one year low of $41.67 and a one year high of $90.98. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of -7.10 and a beta of 2.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.94) by $0.20. The company had revenue of $11.80 million during the quarter, compared to analysts’ expectations of $11.97 million. Ultragenyx Pharmaceutical had a negative net margin of 508.70% and a negative return on equity of 40.10%. Ultragenyx Pharmaceutical’s quarterly revenue was up 5800.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.87) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -3.99 EPS for the current year.

In related news, Director William Aliski sold 19,550 shares of the company’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $72.49, for a total transaction of $1,417,179.50. Following the completion of the sale, the director now owns 72,610 shares of the company’s stock, valued at $5,263,498.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. Insiders have sold 32,250 shares of company stock valued at $2,354,669 in the last ninety days. 8.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Capital International Investors lifted its position in Ultragenyx Pharmaceutical by 20.9% during the third quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock worth $332,834,000 after purchasing an additional 755,127 shares during the period. Capital World Investors lifted its position in Ultragenyx Pharmaceutical by 75.8% during the third quarter. Capital World Investors now owns 1,461,390 shares of the biopharmaceutical company’s stock worth $111,563,000 after purchasing an additional 630,088 shares during the period. Voya Investment Management LLC lifted its position in Ultragenyx Pharmaceutical by 2,221.4% during the second quarter. Voya Investment Management LLC now owns 426,788 shares of the biopharmaceutical company’s stock worth $32,807,000 after purchasing an additional 408,403 shares during the period. First Trust Advisors LP lifted its position in Ultragenyx Pharmaceutical by 29.3% during the third quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock worth $96,453,000 after purchasing an additional 285,961 shares during the period. Finally, Macquarie Group Ltd. bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $20,045,000. 95.39% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Recommended Story: Bond

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply